Special Issue "Clinical Advances on Endometrial Cancer"
Deadline for manuscript submissions: closed (1 June 2021) | Viewed by 18518
Interests: endometriosis; endometrial cancer; estrogen; progesterone; intracrinology; estrogen receptor; progesterone receptor
Special Issues, Collections and Topics in MDPI journals
Interests: endometrial carcinoma; biomarkers; surgical treatment; medical treatment; quality of life
The way we have been looking at endometrial cancer has changed profoundly throughout recent times. Previously considered a disease that could only be cured by surgery, we now recognise that endometrial tumours need more complex and personalised approaches to avoid under- and overtreatment in an already co-morbid population, including diversified approaches in surgical strategy, adjuvant settings and the management of recurrent and metastatic lesions. From a dichotomous histologic classification to guide patients care, we now have four molecular subclasses that help assess accurately risk stratification and improve patient care. These subclasses are slowly making the transition from purely theoretical to being implemented in clinical settings. Our better understanding of the molecular mechanisms underlying the carcinogenic process, together with the identification of biomarkers with prognostic and predictive value, allows for a better use of current drugs and the development of several novel targeted drugs, which are likely to bring, in the near future, radical changes to the way patients are treated.
The landscape of the surgical treatment of endometrial cancer is also changing, with sentinel node and laparoscopic staging procedures, impacting patient risk, quality of life and, possibly, prognosis. Finally, due to the rise in endometrial cancer among premenopausal women, renewed focus on the needs of these women, including better understanding of the pros and cons of fertility sparing treatments or leaving ovaries in situ, in different subgroups is overdue.
The aim of this Special Issue is to gather in one collection reviews and original contributions to illustrate the state of the art and the envisaged future in the management of women with endometrial cancer.
Dr. Andrea Romano
Dr. Erica Werner
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- endometrial cancer
- hormonal therapy
- novel (targeted) treatments
- fertility sparing
- sentinel node
- molecular classification